Amber Peskin, APRN
Clinical Nurse Specialist · New Orleans, LANPI 1992195754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,290 of the $31,672 with a category attached, or 76.7%. Biogen accounts for 74.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $14,892 and has fallen 98.5% since, to $230 in 2025.
Across 48 payments — averaging $659.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$24K
- Genentech USA, Inc.$4K
- Sanofi$4K
- EMD Serono, Inc.$230
- Novartis$72
What the payments were for
- Consulting fees$5,75118%
- Speaking & faculty fees$24,29077%
- Travel & lodging$2351%
- Food & beverage$1,3974%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 30 | $23,542 |
| Genentech USA, Inc. | 6 | $4,299 |
| Sanofi | 9 | $3,529 |
| EMD Serono, Inc. | 2 | $230 |
| Novartis | 1 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical nurse specialist providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 67 | $647,576 |
| TecfideraDimethyl Fumarate | 43 | $456,213 |
| CopaxoneGlatiramer Acetate | 37 | $220,594 |
| EnspryngSatralizumab-Mwge | 13 | $215,013 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 20 | $165,795 |
| AubagioTeriflunomide | 14 | $127,007 |
| Glatiramer Acetate | 47 | $106,081 |
| Plegridy PenPeginterferon Beta-1a | 12 | $95,891 |
| GlatopaGlatiramer Acetate | 27 | $90,825 |
| AmpyraDalfampridine | 11 | $73,510 |
| Dalfampridine ErDalfampridine | 171 | $61,527 |
| Teriflunomide | 81 | $50,970 |
| Dimethyl Fumarate | 60 | $11,937 |
| MyrbetriqMirabegron | 14 | $10,759 |
| Baclofen | 319 | $6,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $23,542 | $456,21343 claims |
| Genentech USA, Inc.Enspryng | $4,299 | $215,01313 claims |
| SanofiAubagio | $3,529 | $127,00714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other clinical nurse specialist in New Orleans
- Roberta McDuffieNew Orleans$2K
- Natalie SantosNew Orleans$1K
- Coletha RileyNew Orleans$773
- Laverne WilliamsNew Orleans$725
- Julie CastexNew Orleans$130
- Lori Quinn-TateBaton Rouge$14K
- Theresa BodkerLafayette$6K
- Louise FrederickLafayette$854
- Florencetta GibsonMonroe$815
- Germaine WallBaton Rouge$103
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.